Polymer Factory Sweden AB launches a new product platform: Dendritic Nanogels

Report this content

Polymer Factory Sweden AB announces the launch of the new dendritic platform Dendritic Nanogels (DNG). Through the launch of this platform, the Company fulfills an operational objective set out for 2022.

On December 1st, Polymer Factory launched the company’s latest dendritic platform, DNG. This is a nanocarrier platform with the potential use as delivery vehicles of pharmaceuticals, peptides, antibiotics etc. It is a novel platform of crosslinked nanoparticles, with features such as water solubility, biocompatibility, and degradability. The DNGs can be programmed to embed functionality and thereby allow them to act as nanoscopic delivery system of therapeutics, fragrances, peptides, and other organic molecules. The DNG technology is envisioned to be desired by different industries, particularly for therapeutic, biomedical and industrial use.

Polymer Factory has pending patents protecting the novel DNG technology.

CTO Michael Malkoch comments:

“We are excited to launch the first generation of DNGs as a new product line of nanocarriers. Our DNGs are unique in the sense of being available as stable and ready-to-formulate products suited to encapsulate and deliver drugs, peptides, biologics and much more. This will allow our customers to straightforwardly screen the performance of their desired active compounds without a large investment in formulation optimization. With this in mind, it’s my belief that the DNG platform can be a contender to the limited number of available delivery platforms such as Lipidic Nanoparticles (LNPs) and Liposomes.”

For more information about Polymer Factory, please contact:
Elin Mignérus, CEO
Phone: +46 (0) 79 300 27 76
E-mail: elin.mignerus@polymerfactory.com

Polymer Factory (publ) is a leading global provider and producer of dendritic materials, with customers ranging from BigPharma, MedTech and BioTech companies, to research-intensive institutes and academic research groups. The Company’s dendritic materials act as smart delivery systems that enhance the effects of the substances they carry, e.g. a vaccine or an anticancer drug. They have also shown great promise in diagnostics, tissue engineering and in the development of vaccines. In addition, Polymer Factory has used the Company’s vast knowledge and expertise to develop a patented calibration technology, named SpheriCal®, designed for Mass Spectrometry instruments. The Company’s dendritic nanotechnologies have the potential to accelerate innovation in technologically demanding sectors, such as MedTech and BioTech. Learn more at www.polymerfactory.com.

Subscribe

Quotes

We are excited to launch the first generation of DNGs as a new product line of nanocarriers. Our DNGs are unique in the sense of being available as stable and ready-to-formulate products suited to encapsulate and deliver drugs, peptides, biologics and much more. This will allow our customers to straightforwardly screen the performance of their desired active compounds without a large investment in formulation optimization. With this in mind, it’s my belief that the DNG platform can be a contender to the limited number of available delivery platforms such as Lipidic Nanoparticles (LNPs) and Liposomes.
Michael Malkoch, CTO